BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Institute of Biomedical Engineering (BME) - ECPv6.16.4.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Institute of Biomedical Engineering (BME)
X-ORIGINAL-URL:https://bme.utoronto.ca
X-WR-CALDESC:Events for Institute of Biomedical Engineering (BME)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220601T120000
DTEND;TZID=America/Toronto:20220601T130000
DTSTAMP:20220520T151856Z
CREATED:20220520T151856Z
LAST-MODIFIED:20220520T151856Z
UID:37406-1654084800-1654088400@bme.utoronto.ca
SUMMARY:Modern Toothpaste Technologies: The Role and Use of Hydroxyapatite in Oral Care
DESCRIPTION:Faculty of Dentistry Research Seminar\nDr. Joachim Enax and Dr. Frederic Meyer\nDr. Kurt Wolff GmbH & Co. KG\,\nBielefeld\, GERMANY\nOver the last years synthetic hydroxyapatite has gained increasing attention as a biomimetic/bionic\noral care agent in preventive dentistry due to its high similarity to human tooth enamel. A significant\nand constantly increasing number of published studies demonstrate its efficacy in various fields of\npreventive oral health care. Currently\, both professional and public debate propagates\nhydroxyapatite as a viable biomimetic alternative to the long-established fluoride in oral care. For\nexample\, hydroxyapatite – in contrast to fluorides – can be used as safe and efficient ingredient for\nkids’ toothpastes because it is safe if swallowed and does not present any risk of fluorosis.\nThe presentation will cover the following topics: \n– Modern toothpaste technologies\, toothpaste ingredients and their functions\n– Hydroxyapatite in oral care\n– Synthesis\, characterization\, safety\, and application fields in dentistry\n– Mechanistic studies (in situ\, in vitro): SEM\, TEM\, TMR etc.\n– Modes of action\n– Clinical studies: RCTs on caries prevention\, gingival health\, reduction of dentin hypersensitivity
URL:https://bme.utoronto.ca/event/modern-toothpaste-technologies-the-role-and-use-of-hydroxyapatite-in-oral-care/
LOCATION:Dentistry Building\, The auditorium (DN 19)\, 124 Edward Street\, 124 Edward Street\, Toronto\, Ontario\, Canada
CATEGORIES:External Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220608T190000
DTEND;TZID=America/Toronto:20220608T200000
DTSTAMP:20220527T201730Z
CREATED:20220527T201730Z
LAST-MODIFIED:20220527T201730Z
UID:37476-1654714800-1654718400@bme.utoronto.ca
SUMMARY:Special session with EngSci alumnus Dr. Amir Manbachi: Towards building a clinically oriented Ultrasound Hub—The journey of an EngSci immigrant to academia
DESCRIPTION:Dr. Amir Manbachi (EngSci 0T8\, BME MAsc 1T0\, PhD 1T5) founded the HEPIUS Innovation Lab\, focusing on the next generation of wearables and implantable medical ultrasound devices for spinal cord injury patients.  Join him for an interactive session where he’ll describe his journey from EngSci to his current position at Johns Hopkins University.
URL:https://bme.utoronto.ca/event/special-session-with-engsci-alumnus-dr-amir-manbachi-towards-building-a-clinically-oriented-ultrasound-hub-the-journey-of-an-engsci-immigrant-to-academia/
CATEGORIES:External Speaker Series
ATTACH;FMTTYPE=image/png:https://bme.utoronto.ca/wp-content/uploads/2022/05/Manbachi_June_2022.png
ORGANIZER;CN="Engineering Science":MAILTO:engsci@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220609T130000
DTEND;TZID=America/Toronto:20220609T150000
DTSTAMP:20220609T152227Z
CREATED:20220511T143904Z
LAST-MODIFIED:20220609T152227Z
UID:37000-1654779600-1654786800@bme.utoronto.ca
SUMMARY:Spotlight on Clinical Translation: Making the leap from the lab bench to Phase I Clinical Trials
DESCRIPTION: \nJoin us for Spotlight on Clinical Translation: Making the leap from the lab bench to Phase I Clinical Trials\, hosted by The Stem Cell Network and Medicine by Design.\nThis workshop will provide investigators and trainees with a basic understanding of the clinical pipeline\, from essential pre-clinical studies to Phase I first in human trials. The invited speakers will review processes involved in clinical trial submission\, regulatory approval and product manufacturing. An interactive Q&A session will ensure participants can ask questions relevant to their research along with leveraging this opportunity to connect with clinical trial experts.\nClinical studies are a key element on the pathway of translational cell and gene therapies. It is\, therefore\, essential that principal investigators\, researchers\, trainees\, clinical research fellows and ecosystem partners working in Canada undertaking translational research have a thorough understanding of the clinical trial pipeline; focused specifically on the early phase clinical trial design processes.\nRegister now!\nRegistration deadline:\nAttendance at this event is limited; all those interested in participating must register by June 8\, 2022\, at 11:59 PM local time.\nView Agenda\n1:00-1:05 pm ET – Opening Remarks\nModerators: Harold Atkins and Darshan Brahmbhatt\n1:05-1:40 pm ET – Presentation by Natasha Kekre\, MD\, Hematologist\, The Ottawa Hospital Transplant and Cellular Therapy Program\, and Scientist\, Ottawa Hospital Research Institute\nPresentation title: Building the pre-CTA and CTA package for Phase I trials: Case study using CLIC CAR-T trial for relapsed/refractory CD19 positive hematologic malignancies\n1:45-2:10 pm ET – Presentation by Patrick Bedford\, MSc\, Managing Director\, weCANreg Consulting Group Inc.\nPresentation title: Leveraging a regulatory rerspective on your path to trials\n2:15-2:40 pm ET – Presentation by Linh Nguyen\, PhD\, Staff Scientist/Head\, Cell Manufacturing Team\, Tumor Immunotherapy Program\, Princess Margaret Cancer Centre\nPresentation title: Developing a cell manufacturing process for an early phase clinical trial\n2:40-2:45 pm ET – Break\n2:45-3:00 pm ET – General Discussion/Q&A session\n3:00 pm ET – Closing Remarks\nSpeaker and Chair Details\nSPEAKERS\nPatrick BedfordNatasha KekreLinh NguyenPatrick Bedford\nPatrick Bedford\, MSc – Managing Director\, weCANreg Consulting Group Inc.\nPatrick Bedford is an experienced and certified regulatory professional who is focused on facilitating global regenerative medicine development. He founded & operates weCANreg Consulting Group Inc.\, which provides regulatory strategy\, interaction\, and submission services. Furthermore\, Patrick is VP of Regulatory & Development at Artisan Bio\, which is a CRISPR-enabled multiplex cell engineering company making precision immunotherapies. In his spare time\, he remains an active educator and contributor to regulatory policy development.\nPrior to incorporating his own company and leading regulatory strategy at Artisan Bio\, Patrick developed regulatory consulting services for a regenerative medicine Network Centre of Excellence; planned 2 Canadian CAR-T New Drug Submissions; and led teams at Health Canada responsible for developing guidance for biosimilars\, transplant material\, and cell & gene therapies. While leading these policy initiatives at Health Canada\, Patrick also supported their Therapeutic Products Classification Committee; chaired the Cells\, Tissues\, and Organs Classification Committee; and championed international harmonization initiatives.\nPatrick completed an Honours Bachelor of Health Sciences degree at the University of Western Ontario\, a Master’s degree in Bioethics and Health Law at the University of Otago\, a Regulatory Affairs Certificate from the Regulatory Affairs Professional Society\, and is pursuing his MBA at the Jack Welch Management Institute.\nNatasha Kekre\nNatasha Kekre\, MD – Hematologist\, The Ottawa Hospital Transplant and Cellular Therapy Program\, and Scientist\, Ottawa Hospital Research Institute \nDr. Natasha Kekre has been appointed to the Department of Medicine in the Division of Hematology\, within the Transplant and Cellular Therapy Program at The Ottawa Hospital\, effective October 2015. She is also an associate scientist within the Ottawa Hospital Research Institute and an associate professor of medicine at the University of Ottawa. She completed her Bachelor’s in Science at the University of Windsor then obtained her medical degree from the University of Ottawa. She then trained at the University of Ottawa in Internal Medicine and Hematology. She went on to do a fellowship in stem cell transplantation at Dana Farber Cancer Institute in Boston\, MA with a Masters in Public Health from Harvard University.\nHer research is focused on developing early phase clinical trials and moving home grown therapeutic strategies into patients. She collaborates with a number of local investigators and scientists in Ottawa\, studying hematologic malignancies and blood and marrow transplant recipients more specifically. She collaborates with scientists and physicians across Canada to build a Canadian CAR-T cell platform (chimeric antigen receptor T cells are immune cells engineered to kill cancer cells)\, bringing this exciting new therapy to Canadian patients. Her other clinical research interests include improving transplant related outcomes and projects with an epidemiologic focus\, including but not limited to decision modeling and meta-analyses.\nShe also participates with a number of cooperative groups in North America including the Center for International Blood and Marrow Transplant Research\, the Canadian Blood and Marrow Transplant Group\, the American Society of Hematology and the American Society for Transplant and Cellular Therapy.\nLinh Nguyen\nLinh Nguyen\, PhD – Staff Scientist/Head\, Cell Manufacturing Team\, Tumor Immunotherapy Program\, Princess Margaret Cancer Centre\nDr. Linh Nguyen has led the Cell Manufacturing Team of the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre since 2005. Dr. Nguyen obtained her PhD in Immunology at the University of Toronto and pursued postdoctoral studies at Harvard Medical School. Her interests include tumor immunology and immunotherapy. Her team has manufactured cell and gene therapy products for clinical trials such as tumor-infiltrating lymphocytes (TILs)\, dendritic cells and T cell receptor gene-engineered T cells. The team’s activities also include quality assurance\, quality control\, and preparation of regulatory submissions.  \nCHAIR\nHarold AtkinsDarshan H. BrahmbhattHarold Atkins\nHarold Atkins\, MD – Attending Physician\, The Ottawa Hospital Transplant and Cell Therapy Program\, and Scientist\, Ottawa Hospital Research Institute\nDr. Harry Atkins is a physician of The Ottawa Hospital Transplant and Cell Therapy Program\, an Associate Professor of Medicine at the University of Ottawa\, and a scientist in the Ottawa Hospital Research Institute’s Center for Innovative Cancer Research.\nHe received his Bachelor of Medical Science degree and Medical Degree from the University of Ottawa followed by a rotating internship year at the Victoria General Hospital in Victoria BC. Specialty training in Internal Medicine was done at the University of Ottawa. Clinical and research fellowships in Hematology\, Stem Cell Transplantation and Experimental Hematology followed at the University of Washington and at the Ontario Cancer Institute.\nHe specializes in hematopoietic stem cell transplantation and has spearheaded the use of stem cell transplantation for immune repair to treat patients with severe autoimmune diseases including multiple sclerosis\, scleroderma\, myasthenia gravis and others. The outcome of a trial using autologous hematopoietic stem cell transplantation to treat multiple sclerosis was published in the Lancet in 2016. He ran a clinical trial exploring the role of hematopoietic stem cell transplantation in preventing organ transplant rejection. He is a member of a BiocanRx funded\, pan-Canadian consortium to develop and improve the accessibility of new chimeric antigen receptor T lymphocytes for the treatment o
URL:https://bme.utoronto.ca/event/spotlight-on-clinical-translation-making-the-leap-from-the-lab-bench-to-phase-i-clinical-trials/
LOCATION:Virtual
CATEGORIES:Events & Workshops,External Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220609T160000
DTEND;TZID=America/Toronto:20220609T170000
DTSTAMP:20220606T140220Z
CREATED:20220606T140220Z
LAST-MODIFIED:20220606T140220Z
UID:37593-1654790400-1654794000@bme.utoronto.ca
SUMMARY:Re-purposing imaging contrast agents for targeted cancer treatment - Princess Margaret Seminar Series
DESCRIPTION:Dr. Xiaohu Gao \nProfessor \nDepartment of Bioengineering and the Center for Nanotechnology \nUniversity of Washington| \n  \nPrincess Margaret Cancer Centre \nDr. Bob Bell Auditorium\, 6th Floor\, 6-604 \nJoin on MS Teams \n  \n*PLEASE NOTE: The seminar will be delivered live in-person at Princess Margaret Cancer Centre\, 6th floor Bob Bell Auditorium\, 610 University Ave and broadcasted via MS TEAMS.\nThose attending the in-person seminar must wear a mask and no food or drink will be permitted. All attendees must be fully vaccinated to enter the hospital. \n 
URL:https://bme.utoronto.ca/event/re-purposing-imaging-contrast-agents-for-targeted-cancer-treatment-princess-margaret-seminar-series/
CATEGORIES:External Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220614T130000
DTEND;TZID=America/Toronto:20220614T140000
DTSTAMP:20220609T150017Z
CREATED:20220609T144415Z
LAST-MODIFIED:20220609T150017Z
UID:37653-1655211600-1655215200@bme.utoronto.ca
SUMMARY:Faculty Search Candidate Talk
DESCRIPTION:This event will be in person only.
URL:https://bme.utoronto.ca/event/faculty-search-talk-2-2022/
LOCATION:MS3153
CATEGORIES:BME Faculty Search
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220615T083000
DTEND;TZID=America/Toronto:20220615T170000
DTSTAMP:20220511T144921Z
CREATED:20220510T210137Z
LAST-MODIFIED:20220511T144921Z
UID:36975-1655281800-1655312400@bme.utoronto.ca
SUMMARY:Toronto Biomedical Engineering Conference 2022
DESCRIPTION:Speakers\n \n  \n\nDr. Michael Snyder\n\nStanford University\n\nMichael Snyder is a Professor and Chair of the Department of Genetics and Director of the Center for Genomics and Personalized Medicine at Stanford University. He is a leader in the field of functional genomics and proteomics and a major participant of the ENCODE project. He is a co-founder of many companies including Personalis\, SensOmics\, Qbio\, January AI\, Filtricine\, Mirvine\, Protos\, Protometrix and Affomix and he is the author of the book “Genomics and Personalized Medicine: What Everyone Needs to Know”. \n\n\n\n\n\n\n\n\n\n\n\n\nDr. Nancy Allbritton\n\n\nUniversity of Washington\n\nDr. Nancy L. Allbritton joined the University of Washington as the Frank & Julie Jungers Dean of Engineering in November 2019. In that capacity\, she serves as the chief academic officer of the college and provides leadership to over 279 faculty and more than 8\,000 students. The College of Engineering is a top-15 nationally ranked public university program with annual research expenditures exceeding $159 million. \nAllbritton is an international expert on multiplexed single-cell assays\, microfabricated platforms for high-content cytometry combined with cell sorting\, and microengineered stem-cell-based systems for recapitulating human organ-level function. Four companies have been formed based on her research discoveries: Protein Simple (acquired by Bio-Techne in 2014)\, Intellego\, Cell Microsystems\, and Altis Biosystems. Allbritton holds an appointment in the UW’s Department of Bioengineering.  She has been nationally recognized for her research and is a Fellow of the American Association for the Advancement of Science\, the American Institute for Medical & Biological Engineering and the National Academy of Inventors. \nPrior to joining the UW\, Allbritton led the Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University which spans two universities and three colleges. \n\n\n\n\n\n\n\n\nDr. Andrew Tsourkas\n\nUniversity of Pennsylvania\n\n\nAndrew Tsourkas\, Ph.D. is a Professor and Undergraduate Chair of Bioengineering at the University of Pennsylvania.  He received his Bachelor’s degree in Mechanical Engineering in 1997 from Cornell University and his Ph.D. in Biomedical Engineering from the Georgia Tech/Emory University joint Ph.D. program in 2002.  He conducted a post-doctoral fellowship in the Department of Radiology at Harvard University\, before joining Penn in 2004. Dr. Tsourkas is currently the Co-Director for the Center for Targeted Therapeutics and Translational Nanomedicine as well as the Chemical and Nanoparticle Synthesis Core. He was a recipient of the Coulter Foundation Early Career Award\, the National Science Foundation CAREER Award\, and was elected fellow of the American Institute for Medical and Biological Engineering. \n\n\n\n\n\n\n\n\n  \n\n\nSchedule\n\n\n\n\nTime\n\n\nActivity\n\n\n\n\n\n\n8:30 – 9:00 AM\n\n\nBreakfast\n\n\n\n\n9:00 – 9:15 AM\n\n\nWelcome from BME Director and ToBE Co-Chairs\n\n\n\n\n9:15 – 10:15 AM\n\n\nFirst Keynote Speaker\n\n\n\n\n10:30 – 11:15 AM\n\n\nWorkshop\n\n\n\n\n\n(1) Mindfulness Moment – Managing Anxiety in Graduate School\n\n\n\n\n\n(2) Building Resilience and Navigating Uncertainty in Graduate School\n\n\n\n\n11:30 – 12:30 PM\n\n\nPoster Session\n\n\n\n\n12:00 – 1:00 PM\n\n\nLunch\n\n\n\n\n1:00 – 2:00 PM\n\n\nOral Presentations\n\n\n\n\n\n(1) Clinical Engineering\n\n\n\n\n\n(2) Cell and Tissue Engineering\n\n\n\n\n\n(3) Molecular Engineering\n\n\n\n\n2:15 – 3:15 PM\n\n\nSecond Keynote Speaker\n\n\n\n\n3:30 – 4:30 PM\n\n\nThird Keynote Speaker\n\n\n\n\n4:30 – 4:45 PM\n\n\nClosing Remarks\n\n\n\n\n6:30 – 10:30 PM\n\n\nPost-Conference Celebration Dinner and Award Ceremony\n\nThe Royal Ontario Museum
URL:https://bme.utoronto.ca/event/toronto-biomedical-engineering-conference-2022/
CATEGORIES:Events & Workshops
ORGANIZER;CN="Toronto Biomedical Engineering Conference (ToBE)":MAILTO:tobeconferenceteam@gmail.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220615T183000
DTEND;TZID=America/Toronto:20220615T223000
DTSTAMP:20220511T144914Z
CREATED:20220510T201717Z
LAST-MODIFIED:20220511T144914Z
UID:36959-1655317800-1655332200@bme.utoronto.ca
SUMMARY:BME Dinner Reception
DESCRIPTION:The 2022 BME Dinner Reception will be hosted at the Royal Ontario Museum to celebrate the achievements of graduate students.\n\n\nBME would like to invite you to the dinner reception at the Royal Ontario Museum (ROM). It has been a crazy last two years and it is a great time for us to get together\, celebrate our achievements\, and meet each other. Students\, faculty\, post-doc\, and administrators will be attending the event. \nThis dinner is free of charge to BME students\, staff\, core faculty members\, and primary cross-appointment faculty members. This will also be extended to non-BME students in core faculty member labs\, research associates in core faculty member labs\, and post-doctoral fellows in core faculty member labs.
URL:https://bme.utoronto.ca/event/bme-dinner-reception/
LOCATION:Royal Ontario Museum\, 100 Queens Park\, Toronto\, ON\, M5S 2C6\, Canada
CATEGORIES:Events & Workshops
ATTACH;FMTTYPE=image/jpeg:https://bme.utoronto.ca/wp-content/uploads/2022/05/e425f089dea4fd7f064a4978a6ca7003-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220621T110000
DTEND;TZID=America/Toronto:20220621T120000
DTSTAMP:20220603T151630Z
CREATED:20220603T151630Z
LAST-MODIFIED:20220603T151630Z
UID:37559-1655809200-1655812800@bme.utoronto.ca
SUMMARY:Insights from the Endotronix Journey: A PMA Medtech “Startup" Story
DESCRIPTION:Please join us for an ECHO webinar on Tuesday June 21\, 2022 (11 am – 12 pm EST) featuring Dr. Harry Rowland (CEO and Co-founder\, Endotronix). Dr. Rowland’s presentation entitled\, “Insights from the Endotronix Journey: A PMA Medtech “Startup” Story”\, will feature an overview of Endotronix\, its technologies and the story behind its success. Endotronix is a medical technology company\, delivering an integrated platform that provides comprehensive\, reimbursable health management innovations for patients suffering from advanced heart failure. Please see attachment for more details. \n\nRegister in advance for this webinar: https://us02web.zoom.us/meeting/register/tZwkc-GrqD0sGtcnluN7KLI2wNtAxZ1kYIx9 \nAfter registering\, you will receive a confirmation email containing information about joining the webinar. \n  \nECHO is an entrepreneurship training program\, funded and organized in a partnership between (i) the Translational Biology and Engineering Program (TBEP)\, the University of Toronto component of the Ted Rogers Centre for Heart Research\, and (ii) the Health Innovation Hub (H2i).
URL:https://bme.utoronto.ca/event/insights-from-the-endotronix-journey-a-pma-medtech-startup-story/
CATEGORIES:External Speaker Series
ORGANIZER;CN="Translational Biology and Engineering Program (TBEP)":MAILTO:reception.tbep@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220621T120000
DTEND;TZID=America/Toronto:20220621T130000
DTSTAMP:20220621T153842Z
CREATED:20220520T150058Z
LAST-MODIFIED:20220621T153842Z
UID:37389-1655812800-1655816400@bme.utoronto.ca
SUMMARY:Global Speaker Series: Gilbert Bernier\, PhD - Université de Montréal
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians.\nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Gilbert Bernier\, PhD\, Associate Professor in the Department of Neuroscience at Université de Montréal.\nThe title of this talk will be\, “Cone photoreceptor sheet transplantation for the treatment of macular degenerations”\nRegister now\nHybrid event\, with in-person and virtual options\nIn-person will be held at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room.\nVirtual event links will be sent after registration. \nMore About Gilbert bernier:\nProfessor Gilbert Bernier performed is graduated studies in Molecular Biology at Montreal University where he characterized the gene mutated in the mouse neurological disorder dystonia musculorum. In 1997\, he moved to the Max-Planck Institute of Biophysical Chemistry in Germany to study developmental biology of the retina. Since 2001\, he is heading the laboratory of stem cell and developmental biology at Maisonneuve-Rosemont Hospital to exploit the potential of human pluripotent stem cells for the study and treatment of neurodegenerative diseases such as retinal degenerative diseases and Alzheimer’s disease. Professor Bernier has also contributed to the characterization of Polycomb group proteins function in brain cancer\, DNA repair\, and premature ageing. He is Professor at the Neuroscience Department of Montreal University since 2012. He is co-founder and CEO of StemAxonTM\, a Canadian corporation involved in the development of new treatments for neurodegenerative diseases.\n Learn more about Gilbert Bernier
URL:https://bme.utoronto.ca/event/global-speaker-series-gilbert-bernier-phd-universite-de-montreal/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:External Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220623T130000
DTEND;TZID=America/Toronto:20220623T140000
DTSTAMP:20220609T150225Z
CREATED:20220609T144131Z
LAST-MODIFIED:20220609T150225Z
UID:37649-1655989200-1655992800@bme.utoronto.ca
SUMMARY:Faculty Search Candidate: Designer polymer excipients to enable next-generation insulin formulations
DESCRIPTION:Caitlin Maikawa\, PhD\nAbstract: Insulin was first isolated a century ago\, yet commercial formulations of insulin for hormone replacement therapy fall short of mimicking the endogenous glycemic control that occurs in non-diabetic individuals. Moreover\, diabetes management is increasingly relying on automated insulin delivery using closed-loop systems to improve glucose management and reduce patient burden. However\, improvements in insulin formulations\, sensors\, and algorithms are required to shift from hybrid systems to fully autonomous delivery. Insulin formulations that better mimic secretion from the beta-cells\, by enabling more rapid insulin absorption kinetics and/or co-delivering complementary hormones (i.e. amylin)\, would improve diabetes management. However\, formulation innovation is complicated by the poor stability of insulin monomers and amylin. Here\, I will discuss two polymeric excipient platforms (non-covalent PEGylation and amphiphilic copolymer excipients) that can be used to increase the stability of insulin in formulation and modulate insulin pharmacokinetics. Using these designer excipients\, I have developed three insulin formulations: (i) an ultrafast monomeric insulin lispro\, (ii) an insulin-amylin co-formulation and (iii) an ultrafast co-formulation. These enhanced insulin formulations are promising candidates to address formulation challenges related to achieving fully autonomous insulin delivery\, improve glucose control\, and reduce the burden of treatment management for patients with diabetes.
URL:https://bme.utoronto.ca/event/designer-polymer-excipients-to-enable-next-generation-insulin-formulations/
LOCATION:MS2172
CATEGORIES:BME Faculty Search
END:VEVENT
END:VCALENDAR